AN2 Therapeutics, Inc. (ANTX)

Market Cap	135.64M +301.7%
Revenue (ttm)	n/a
Net Income	-33.99M
EPS	-1.13
Shares Out	27.40M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	604,020
Open	5.430
Previous Close	5.440
Day's Range	4.780 - 5.470
52-Week Range	1.000 - 6.910
Beta	-0.03
Analysts	Buy
Price Target	2.00 (-59.6%)
Earnings Date	Mar 25, 2026

About ANTX

AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company’s initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis. It also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials; and has ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 25, 2022
• Employees: 22
• Stock Exchange: NASDAQ
• Ticker Symbol: ANTX
• Website: https://www.an2therapeutics.com

Analyst Summary

According to one analyst, the rating for ANTX stock is "Buy" and the 12-month stock price target is $2.0.

Price Target

$2.0

(-59.60% downside)

Analyst Consensus: Buy